CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
CCTG is pleased to announce that the 2026 Annual Spring Meeting of Participants will be held April 24-26, 2026, at the Chelsea Hotel in Toronto.
The MYC2 trial (SWOG S1803) - A Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study) - has closed Step #1 registration of new study participants having successfully reach the target accrual goal (n=1420 for Screening Step). Step #2 and Step #3 remain open.
Above: Dr. Rahima Jamal and Camille Amiel prepare the patient to take the fecal microbiota capsules. Photo: Centre hospitalier de l’Université de Montréal (CHUM)
français: La période d’inscription à l’essai novateur sur le mélanome ME17 est commencée.
CCTG will be holding the next CRA Lunch and Learn on Wednesday January 22nd, 2025, at 12 pm ET. Session 2 will cover the topic of CCTG Website Navigation and Communications.
The CCTG Gastro-Intestinal Disease Site Committee would like to recognize Dr Vincent Barrette and Dr Anthony Lott for their accrual contributions to the CRC10 study as new investigators.
MA41 trial investigating a de-Escalation of adjuvant chemotherapy in HER-2 positive, estrogen receptor-negative, node-negative, early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and dual HER-2 blockade (DECRESCENDO) trial has now permanently closed.
In April 2024, at the CCTG Spring Meeting of Participants, the CCTG Patient Representative Committee members participated in a facilitated session designed to identify the research topics that Committee members view as being most important to cancer patients and caregivers. The outcome of the workshop resulted in the identification by the CCTG reps of six Cancer Research Priorities.
